Neurocrine Biosciences is involved in neurology and endocrinology research and therapy, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, self-described as addressing unmet medical needs.

Neurocrine Biosciences

Neurocrine Events

Domain Not Resolving

HSTS

DNSSEC

HSTS IncludeSubdomains PreLoad

Microsoft

Common Name Invalid

Japanese Yen

Amazon CloudFront

Amazon Route 53

Amazon SSL

VP, Deputy General Counsel

Ayesha Zierhut

Deputy General Counsel

Christine Bowden

Chief Legal Officer

Darin Lippoldt

Chief Medical Officer

Eiry Roberts MD

Owner

Elizabeth Encinas

Chief Commercial Officer

Eric Benevich

Board Director

George Morrow

Chief Scientific Officer

Jude Onyia

Chief Human Resources Officer

Julie Cooke

Mgr., IR and Internal Communications

Kevin Gorman

Richard Pops

Shalini Sharp

William Rastetter

Leslie V. Norwalk

Kevin C. Gorman

Christopher O'Brien

David Boyer

Chief Corporate Affairs Officer

Eiry Roberts

Dimitri Grigoriadis

Chief Research Officer

Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company.

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Investors Active in Burnaby, British Columbia

Western US Biotechnology Public Companies

San Diego Companies (Top 10K)

Western US Public Companies With More Than $500 in Revenue

Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.

Post-IPO Equity - Neurocrine Biosciences

Venrock

Medical and Beauty Services and Agricultural Services

San Diego

California

United States

North America

Why Neurocrine Biosciences Stock Was Tumbling This Week

Neurocrine Biosciences to Participate at Investor Conferences in September

Neurocrine introduces INGREZZA sprinkle for dysphagia patients

Neurocrine Biosciences Executives Sell Shares

Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont

Neurocrine Biosciences Announces CEO Succession Plan

Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study

US FDA approves Neurocrine Biosciences' movement disorder drug

Neurocrine Biosciences Reports First Quarter 2024 Financial Results

Singapore

Asia

India

United Kingdom

Europe

Australia

Oceania

HTML5

Lightbox

Gravity Forms

Google Fonts

Wordpress

Modernizr

Apache Server

Google Compute Engine

Google Analytics

Office 365

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL  Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Sep 18, 2024 4:07 AM	a2507801
public peers	general	Sep 17, 2024 5:10 AM	c422ab64
news daily refresh	general	Dec 4, 2024 2:16 PM	cedc0db7
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 17, 2024 5:24 AM	fccf78af
company summary	general
signals	general	Sep 17, 2024 5:10 AM	d6261cc3
crunchbase trigger	general	Nov 4, 2024 10:53 AM	3e2bce5c
crunchbase profile	general	Nov 4, 2024 1:41 PM	1f4ce7b8
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	80d0d265
peers	general	Sep 17, 2024 5:10 AM	4f3167f1
news basic	general	Dec 4, 2024 2:13 PM	978070bb
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NEUROCRINE

Neurocrine Biosciences

Last Close

125.00

22/11 21:00

Market Cap

14.81B

Beta: -

Volume Today

1.18M

Avg: -